Skip to content
Screener

Medtronic MDT Neuroscience — Selling, general, and administrative expense

Other segment segments

Cardiovascular
$1.19B+17.4%
Medical Surgical
$650M+9.6%
Diabetes
$300M+12.8%

Similar metrics at other companies

Materion logo
MTRNOther — Selling, general, and administrative expense
$11.73M+59.5%
SKY
SKYTLegacy SkyWater — Selling, general, and administrative expense
$25.97M+72.8%
SKY
SKYTSkyWater Texas — Selling, general, and administrative expense
$6.47M
Materion logo
MTRNElectronic Materials — Selling, general, and administrative expense
$10.72M+17.5%
Materion logo
MTRNPerformance Materials — Selling, general, and administrative expense
$14.88M+4.5%
Materion logo
MTRNPrecision Optics — Selling, general, and administrative expense
$4.99M+15.6%

Other financials

Income statement

See full
Revenue$9.8B+9.9%
Gross profit$6.4B+10.9%
Operating income$1.9B+30.4%
Net income$1.2B+17.8%
EPS (diluted)$0.97+18.3%

Balance sheet

See full
Cash & equivalents$1.9B-12.1%
Total debt$29.2B-1.6%
Total equity$49.5B+3.0%
Total assets$93.0B+1.5%

Cash flow

See full
Operating cash flow$2.6B+1.8%
CapEx$488.0M+6.3%
Free cash flow$2.1B+0.8%

Valuation

See full
Market cap$110.07B-3.9%
Enterprise value$137.33B-3.2%
P/E22.9×-1.6×
P/S-0.3×

Profitability

See full
Gross margin65%-0.3pp
Operating margin17.8%0.0pp
Net margin13.2%-0.7pp
FCF margin14.9%-0.5pp

Returns & leverage

See full
Return on equity9.8%+0.4pp
Debt / equity0.6×0.0×
Current ratio2.1×+0.3×

Where this comes from

Reported directly by Medtronic in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Medtronic’s 10-K, filed June 18, 2026.

Filed
Jun 18, 2026, 4:27 PM EDT
Fiscal year
FY2026
Accession
0001628280-26-044354
(in millions)CardiovascularNeuroscienceMedical SurgicalTotal
Less:
Cost of products sold, excluding amortization of intangible assets4,6953,1513,47611,323
Research and development expense1,1366166862,438
Selling, general, and administrative expense4,5193,4212,51110,451
Other segment items(3)(46)36144
Reportable segment operating profit$3,672$3,062$2,128$8,862
Reconciliation of segment profit / (loss)
Other operating segments profit(1)106

Item 8. Financial Statements and Supplementary Data

FAQ

What is Medtronic's neuroscience — selling, general, and administrative expense?
Medtronic (MDT) reported neuroscience — selling, general, and administrative expense of $875M in Q1 2026.
How has Medtronic's neuroscience — selling, general, and administrative expense changed year-over-year?
Medtronic's neuroscience — selling, general, and administrative expense increased by 7.6% year-over-year, from $813M to $875M.
What is the long-term trend for Medtronic's neuroscience — selling, general, and administrative expense?
Over 3 years (2023 to 2026), Medtronic's neuroscience — selling, general, and administrative expense has grown at a 16.0% compound annual growth rate (CAGR), from $2.19B to $3.42B.
What does neuroscience — selling, general, and administrative expense mean?
This covers the costs of marketing, sales force compensation, legal, and administrative support functions dedicated to the Neuroscience segment. It reflects the operational overhead required to maintain market presence and support customer relationships.

Ask your AI about Medtronic's neuroscience — selling, general, and administrative expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude